Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 947432, 8 pages
Clinical Study

The Use of Humoral Responses as a Marker of CMV Burden in HIV Patients on ART Requires Consideration of T-Cell Recovery and Persistent B-Cell Activation

1School of Pathology and Laboratory Medicine, University of WA, Nedlands, WA 6009, Australia
2Microbiology and Infectious Diseases, Royal Perth Hospital, Perth, WA 6000, Australia
3Clinical Immunology and Immunogenetics, Royal Perth Hospital, Perth, WA 6000, Australia
4Immunology & Immunopathology, PathWest Laboratory Medicine, Nedlands, WA 6009, Australia
5Medicine and Pharmacology, University of WA, Nedlands, WA 6009, Australia

Received 12 September 2014; Accepted 30 October 2014; Published 23 November 2014

Academic Editor: Giuseppe Murdaca

Copyright © 2014 Samantha J. Brunt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary Tables 1 and 2 provide results of multivariate modelling and interactions described in the text. Table 1 provides results of longitudinal multivariate modelling for (ln)CMVgB antibody with time. Equation is polynomial, and was found to be similar for both (ln)CMVgB and (ln)CMV lysate antibodies. Levels of antibodies and inflammatory markers described in Figures 1 and 2 were tested as covariates in the model for (ln)CMVgB antibody over time. Results of associations for each covariate are reported in the Table, alongside interaction terms that were found to be significant. Supplementary Table 2 provides results of multivariate linear regression modelling for levels of (ln)CMV lysate, CMVgB or CMV IE-1 antibody with (inv)sBAFF for HIV patients and controls, demonstrating a difference in the association of CMVgB antibody and sBAFF in HIV patients compared to controls.

  1. Supplementary Material